tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Perseus Proteomics Reports Increased Sales but Continued Losses

Story Highlights
Perseus Proteomics Reports Increased Sales but Continued Losses

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an announcement.

Perseus Proteomics Inc. reported its financial results for the nine months ending December 31, 2024, showing a small increase in net sales by 15.9% compared to the previous year. Despite this, the company continues to experience financial losses, with a net loss recorded. The financial position showed an increase in total assets and net assets, but the company refrained from providing a forecast for the fiscal year ending March 31, 2025, citing difficulties in making rational predictions.

More about Perseus Proteomics, Inc.

Perseus Proteomics Inc. operates within the biotechnology industry, focusing on the development and commercialization of antibody-based products and services. The company is listed on the Tokyo Stock Exchange and engages in the research and development of therapeutic antibodies.

YTD Price Performance: 3.38%

Average Trading Volume: 871,891

Technical Sentiment Consensus Rating: Sell

Current Market Cap: Yen8.56B

See more insights into 4882 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1